Introduction {#sec1-1}
============

In the WHO 2008 criteria revised in 2016, for a patient with clinical and other laboratory features, a presumptive diagnosis of myelodysplastic syndrome (MDS) can be made if a specific clonal chromosomal abnormality is present. The balanced abnormalities included in the 2008 criteria were t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21.1), t(2;11)(p21;q23), inv (3) (q21q26.2), and t (6;9)(p23;q34),\[[@ref1]\] while those further included in the 2016 criteria were t(5;12)(q32;p13.2), t(5;7)(q32;q11.2), t(5;17) (q32;p13.2), t(5;10)(q32;p21.2), and t(3;5) (q25.3;q35.1).\[[@ref2]\] Recently, we encountered a patient with pancytopenia and what appears to be an extremely rare chromosomal abnormality, t(10;18)(q26;q21). As there was no obvious dysplasia or increase in blasts, we considered this reciprocal translocation as a "balanced abnormality" and diagnosed the patient with MDS, unclassified (MDS--U) according to the WHO classification system. The following case report further describes this chromosomal abnormality.

Case Report {#sec1-2}
===========

An 82-year-old male suffering from severe chest pain was taken by ambulance to a clinic. The day after, he received coronary angiography, and stenosis was observed in the right coronary artery. His chest pain persisted after angiography. Unstable angina was suspected, and the patient was transferred to the Cardiovascular Medicine Department at the Tohoku Medical and Pharmaceutical University Hospital to receive a percutaneous coronary intervention.

Upon admission to our hospital, the patient\'s white blood cell count was slightly low (3,400/μL), and low red blood cell (2.65 × 10^6^/μL), hemoglobin (9.3 g/dL), and platelet(118,000/μL) levels were also observed \[[Table 1](#T1){ref-type="table"}\]. Echocardiography revealed severe aortic valve stenosis. Aortic valvuloplasty and coronary artery bypass graft surgery were performed. During the surgery, bone marrow aspiration from the sternum was performed. The aspiration was examined morphologically and cytogenetically. The patient\'s bone marrow was observed to be hypocellular with no obvious dysplasia \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]. The blast percentage was within the normal range at 0.6% \[Figure [1A](#F1){ref-type="fig"} and [B](#F1){ref-type="fig"}, and [Table 1](#T1){ref-type="table"}\]. G-banding analysis of the bone marrow sample revealed that the patient had a chromosomal translocation: among the 20 cells analyzed, three cells were karyotype A (45, X,-Y), 13 cells were karyotype B (45, idem, t(10;18)(q26;q21), and four cells were karyotype C (46, XY) \[[Figure 1C](#F1){ref-type="fig"}\]. The patient was diagnosed with MDS--U. The patient remains carefully observed in our hospital as an outpatient thereafter.

###### 

Laboratory findings at first visit and the result of bone marrow examination

  Complete blood count          
  ----------------------------- -------------------------
  WBC                           3.4×10^3^/μL
  Seg                           58.7%
  Eosino                        3.6%
  Baso                          0.6%
  Lymph                         25.8%
  Mono                          11.3%
  RBC                           2.65×10^6^/μL
  Hb                            9.3g/dL
  Ht                            28%
  MCV                           105.4fL
  PLT                           18×10^3^/μL
  PT                            14.4 sec
  APTT                          28.5 sec
  D-dimer                       2.91 μg/mL
                                
  **Biochemistry test**         
                                
  T-Bil                         0.7 mg/dL
  AST                           33 U/L
  ALT                           28 U/L
  LD                            167 U/L
  ALP                           209 U/L
  g-GTP                         63 U/L
  CK                            41 U/L
  CK-MB                         \<10 U/L
  Troponin T                    0.017 ng/mL
  BUN                           15mg/dL
  CRE                           1.2mg/dL
  UA                            5.3mg/dL
  TP                            6.2mg/dL
  Alb                           3.7mg/dL
  T-CHO                         154mg/dL
  HDL-C                         56mg/dL
  LDL-C                         85mg/dL
  Na                            141mEq/L
  K                             4.1mEq/L
  Cl                            111mEq/L
  Ca                            8.7mg/dL
  IP                            3.1mg/dL
  Fe                            92μg/dL
  UIBC                          131μg/dL
  TIBC                          223μg/dL
  Ferritin                      155ng/mL
  Zn                            62μg/dL
  CRP                           0.05mg/dL
  BNP                           58.6pg/mL
  FBS                           121mg/dL
  HbA1c                         5.5%
                                
  **Bone marrow examination**   
                                
  **Cellularity**               **hypocellular marrow**
                                
  M/E                           2.6
  Blast                         0.6%
  Promyelo                      2.2%
  Myelo                         9.4%
  Meta                          11.4%
  Stab                          14.4%
                                
  **Bone marrow examination**   
                                
  **Cellularity**               **hypocellular marrow**
                                
  Seg                           16.8%
  Eosino                        5.4%
  Baso                          0.2%
  Mono                          3.6%
  Lymph                         11.8%
  Plasma                        0.4%
  Macrophage                    0.8%
  Proeryth                      0%
  Basoeryth                     0.2%
  Polyeryth                     21.4%
  Orthoeryth                    0.2%

![Morphological images of bone marrow aspirations at the initial diagnosis using Wright--Giemsa staining and a result of G-banding chromosomal analysis. (A) Morphological image with × 100 magnification. Hypocellular marrow with lipid droplets was observed. (B) Image at × 1000 magnification. No apparent dysplasia was observed. (C) A G-banded karyotype showing 45, X,-Y\[3\]/45, idem, t(10;18)(q26;q21)\[13\]/46,XY\[4\]. Arrows indicate translocated regions](JLP-11-382-g001){#F1}

Discussion {#sec1-3}
==========

We recently reported the usefulness of careful histogram analysis of automatic blood cell analyzer results for acute leukemia, which assists with rapid morphological findings for blasts and abnormal cells.\[[@ref3]\] However, not only morphologic but also cytogenetic studies are necessary to diagnose hematologic malignancies; this is common knowledge for clinical hematologists. A unique feature of the present case may be that the bone marrow aspiration and chromosome analysis were ordered and performed by cardiovascular surgeons rather than hematologists during the aortic valvuloplasty and coronary artery bypass graft surgery.

We speculate that the most likely gene playing a role in the pathogenesis of this patient\'s disease is BCL2. The BCL2 gene lies within 18q21.3 and is frequently translocated to the immunoglobulin heavy chain (IgH) gene enhancer region as a result of t(14;18)(q32;q21.3), which results in the over-expression of the BCL2 gene.\[[@ref4]\] BCL2 overexpression is involved in the pathogenesis of follicular lymphoma by preventing apoptosis of the germinal center B-cells.\[[@ref4]\] The t(14;18)(q32;q21.3) translocation can be detected by fluorescence *in situ* hybridization in 85% of all cases and is considered a molecular hallmark of this disease.

Not only follicular lymphoma but also several other hematopoietic malignancies are reported to be related to the aberrant expression of the BCL2 protein.\[[@ref5]\] In particular, in MDS patients, BCL2 expression is high, while in aplastic anemia patients, BCL2 expression is low.\[[@ref5]\] Previously, it was reported that progression to high-risk MDS correlates with elevated expression of BCL2 protein.\[[@ref6]\] Collectively, BCL2 expression and regulation may affect the pathophysiology of MDS.

Chromosome 10 and 18 translocations are very rare. To the best of our knowledge, only four studies have reported such translocations.\[[@ref7][@ref8][@ref9][@ref10]\] In particular, the breakpoint we observed, t(10;18)(q26;q21), was unique because it is not among these reported translocations. Although we could not identify what was fused with the gene residing in 18q21.3 (possibly the BCL2 gene), since this patient is too stable to perform further analysis, these results indicate that characterizing the gene (s) affected by this rare translocation may lead to further understanding of the biology of MDS.
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